Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Venue 22
About the venue
Rooms
Call for abstracts
Programme 22
Tracks 22
Speakers 22
Side events 22
Subscribe
days
hours
minutes
seconds
Epidemiology
Sessions
Wednesday, 23 November
10:50
Gambling Research
10:50
to
12:20
Insights zone 3 (I3)
Oral presentation session
13:20
Gambling epidemiology and new trends
13:20
to
14:50
Insights zone 3 (I3)
Oral presentation session
15:00
Estimating harm
15:00
to
16:30
Central square 3 (C3)
Oral presentation session
Estimating prevalence
15:00
to
16:30
Knowledge market 4 (K4)
Oral presentation session
Injecting-related infections and drug surveillance
15:00
to
16:30
Knowledge market 3 (K3)
Oral presentation session
Spillover effects of drug policy and why better data are needed
15:00
to
16:30
Networking zone 1 (N1)
e-poster guided tour
Substance use and mental health disorders in Europe: prevalence, models of care, and implementation in a challenging COVID-19 context
15:00
to
16:30
Knowledge market 2 (K2)
Structured session
Surveillance
15:00
to
16:30
Networking zone 4 (N4)
Short communication session
16:50
Alcohol use disorder treatment and its epidemiology
16:50
to
18:20
Central square 1 (C1)
Oral presentation session
Driving under the influence of cannabis (DUIC)
16:50
to
18:20
Insights zone 3 (I3)
Structured session
Focusing on gender issues
16:50
to
18:20
Central square 3 (C3)
Oral presentation session
Thursday, 24 November
09:00
The Spanish Network on Research on Primary Attention on Addiction (RIAPAd): a new multilevel integrated model of responsible research on Addiction Disorders
09:00
to
10:30
Knowledge market 4 (K4)
Structured session
10:50
Cannabis use and purchase behaviours in Canada, United States, Australia, and New Zealand: Findings from the International Cannabis Policy Study
10:50
to
12:20
Knowledge market 1 (K1)
Structured session
Current international evidence on prevalence and perceptions of Heated Tobacco Products (HTPs)
10:50
to
12:20
Insights zone 4 (I4)
Structured session
Problematic internet and videogame use
10:50
to
12:20
Insights zone 3 (I3)
Oral presentation session
13:20
Methods and Problems with Estimating Prevalence of People Who Inject Drugs, studies and debate on how to get better and more consistent estimates in Europe and Rest of the World
13:20
to
14:50
Central square 2 (C2)
Structured session
15:00
Alcohol epidemiology and interventions
15:00
to
16:30
Networking zone 3 (N3)
Short communication session
Insights into acute recreational drug and new psychoactive substance toxicity – an update from the Euro-DEN Plus Project
15:00
to
16:30
Central square 2 (C2)
Structured session
The future of surveys in the field of alcohol research: Lessons learned from a large-scale European survey (DEEP SEAS project)
15:00
to
16:30
Central square 1 (C1)
Structured session
16:50
Insights from treatment I
16:50
to
18:20
Central square 3 (C3)
Oral presentation session
Prison and drugs: exploring social determinants and pathways to drug problem and incarceration
16:50
to
18:20
Central square 1 (C1)
Structured session
Reducing harm - obstacles and opportunities
16:50
to
18:20
Networking zone 1 (N1)
e-poster guided tour
Substance use, suicide and self-harm: epidemiology and prevention
16:50
to
18:20
Main stage
Structured session
Young people, substance use and prevention
16:50
to
18:20
Knowledge market 3 (K3)
Oral presentation session
Friday, 25 November
09:00
Alcohol addiction; new knowledge on politics, risks, treatments and outcomes
Social inequality in drinking, underage drinking and alcohol industry
09:00
to
10:30
Main stage
Plenary session
10:50
A Digital Future? Engaging online communities of people who use drugs to influence policy and practice
10:50
to
12:20
Central square 4 (C4)
Workshop
COVID-19-adapted addiction services and impact for service users
10:50
to
12:20
Insights zone 4 (I4)
Structured session
Mortality among people who use drugs
10:50
to
12:20
Knowledge market 3 (K3)
Oral presentation session
Substance use and prison
10:50
to
12:20
Central square 1 (C1)
Oral presentation session
13:20
Alcohol psychology and some epidemiology
13:20
to
14:50
Networking zone 4 (N4)
Short communication session
Changes and trends in how people are buying drugs
13:20
to
14:50
Insights zone 4 (I4)
Oral presentation session
New advances in alcohol clinical research: evidence from three large National Institute for Health Research-funded randomised controlled trials
13:20
to
14:50
Networking zone 3 (N3)
Structured session
Substance use, mental health risk and suicide
13:20
to
14:50
Knowledge market 2 (K2)
Oral presentation session
Understanding drug use, risk and harm
13:20
to
14:50
Networking zone 2 (N2)
e-poster guided tour
Using innovative data or methods to assess drug markets and drug policy impacts
13:20
to
14:50
Knowledge market 1 (K1)
Oral presentation session
15:00
The Richard Hartnoll memorial lecture
15:00
to
15:30
Main stage
Plenary session
Presentations
Wednesday, 23 November
10:50
Oral presentation
Treatment-seeking problem gamblers: characteristics of individuals who offend to finance gambling
10:50
to
12:20
Insights zone 3 (I3)
Amanda Roberts
Oral presentation
Characterizing habit formation in modern slot machine gambling
10:50
to
12:20
Insights zone 3 (I3)
Luke Clark
Oral presentation
A scoping review on cryptocurrency trading among young people and its association with gambling and mental health
10:50
to
12:20
Insights zone 3 (I3)
Benjamin Johnson
Oral presentation
Cue-reactivity and inhibitory control in behavioral addcitions: an overview of functional neuroimaging studies
10:50
to
12:20
Insights zone 3 (I3)
Kjell Büsche
13:20
Oral presentation
Cryptocurrency trading as behavioral addiction: cross-sectional and longitudinal perspective from Finland
13:20
to
14:50
Insights zone 3 (I3)
Atte Oksanen
Oral presentation
Online gambling and associated harms during the COVID-19 pandemic: A population study
13:20
to
14:50
Insights zone 3 (I3)
Sylvia Kairouz
Oral presentation
Online gambling and F2P games in Canada: portrait and trends
13:20
to
14:50
Insights zone 3 (I3)
Annie-claude Savard
Oral presentation
Problem gambling among European adolescents: potential risk of gambling products and online gambling
13:20
to
14:50
Insights zone 3 (I3)
Elisa Benedetti
15:00
Short communication
The Unit of Cannabis: from a systematic review to a NIDA recommendation
15:00
to
16:30
Networking zone 4 (N4)
María Teresa Pons-cabrera
Short communication
A longitudinal study of a drug checking service for patrons of Boom Festival 2018: behavioral outcomes at individual and group levels.
15:00
to
16:30
Networking zone 4 (N4)
Helena Valente
Short communication
Using Reddit Social Media Data to Uncover Self-medication and Drug Use Trends among Opioid Users: Semi-automated Natural Language Processing Approach.
15:00
to
16:30
Networking zone 4 (N4)
Georgiy Bobashev
Short communication
Findings from novel methods of surveillance for fentanyl and novel psychoactive substances within Supervised Injecting Facilities
15:00
to
16:30
Networking zone 4 (N4)
Suzanne Nielsen
Short communication
Detection of Potent 'Nitazene' Synthetic Opioids by a networked drug checking service in Toronto, Ontario, Canada
15:00
to
16:30
Networking zone 4 (N4)
Kristy Scarfone
Short communication
Access to medical cannabis in Brazil: informal regulation via patient associations as a social movement
15:00
to
16:30
Networking zone 4 (N4)
Paulo J. R. Pereira
Short communication
Method development for monitoring Google-indexed e-shops offering new psychoactive substances (NPS) in The Netherlands.
15:00
to
16:30
Networking zone 4 (N4)
Lavinia Stegemann
Short communication
How to evaluate complex drug policies? A case study of the Belgian drug policy
15:00
to
16:30
Networking zone 4 (N4)
Eva Blomme
Oral presentation
2. Impact of Covid19 on mental health and drug use: main findings from the EMCDDA trendspotter study
15:00
to
16:30
Knowledge market 2 (K2)
Franca Beccaria
Oral presentation
3. Psychiatric comorbidity in the European countries: prevalence and models of care
15:00
to
16:30
Knowledge market 2 (K2)
Francina Fonseca
Oral presentation
4. The dual diagnosis inpatient and outpatient treatment program in Ljubljana: practical implementatio
15:00
to
16:30
Knowledge market 2 (K2)
Nusa Segrec,
Andrej Kastelic
Discussion
Discussion: Substance use and mental health disorders in Europe
15:00
to
16:30
Knowledge market 2 (K2)
Gabriele Fischer
Oral presentation
1. What do we mean by psychiatric comorbidity or dual disorders?
15:00
to
16:30
Knowledge market 2 (K2)
Marta Torrens
Oral presentation
Fear of inpatient opioid withdrawal: Addressing a modifiable barrier to health-care access for people who use illicit opioids.
15:00
to
16:30
Knowledge market 3 (K3)
Magdalena Harris
Oral presentation
Analysis of drugs in used syringes from sentinel European cities, 2020
15:00
to
16:30
Knowledge market 3 (K3)
Thomas Seyler
Oral presentation
The impact of opioid agonist treatment on hospitalisations for injecting-related diseases: a retrospective data linkage study
15:00
to
16:30
Knowledge market 3 (K3)
Samantha Colledge-Frisby
e-poster
Association of the 2016 UK Psychoactive Substance Act with hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure.
15:00
to
16:30
Networking zone 1 (N1)
Sam Craft
e-poster
Is there a long-term relationship between cannabis and heroin use? An 18-20-year follow-up of the Australian Treatment Outcome Study (ATOS)
15:00
to
16:30
Networking zone 1 (N1)
Jack Wilson
e-poster
Do Medical Cannabidiol Laws Reduce Nonfatal and Fatal Opioid Overdose Rates?
15:00
to
16:30
Networking zone 1 (N1)
Rahi Abouk
e-poster
Regulating cannabis : a comparative perspective on policy rollouts and unintended consequences in The United States and Canada (lessons from 6 case studies)
15:00
to
16:30
Networking zone 1 (N1)
Ivana Obradovic
e-poster
The Effects of Recreational Cannabis Laws on Pharmacy- and Hospital-Based Opioid Distribution in the United States
15:00
to
16:30
Networking zone 1 (N1)
Coleman Drake
Oral presentation
Trends in mortality from alcohol, opioid, and combined alcohol and opioid poisonings by sex, educational attainment and race and ethnicity for the United States 2000-2018.
15:00
to
16:30
Central square 3 (C3)
Charlotte Buckley
Oral presentation
Mortality consequences of misuse of psychoactive prescription drugs in Portugal - the MisuMedPT project
15:00
to
16:30
Central square 3 (C3)
Ana Araújo
Oral presentation
Utilising data linkage to describe and explore mortality among a retrospective cohort of individuals admitted to residential substance use treatment.
15:00
to
16:30
Central square 3 (C3)
Tisdale Calvert
Oral presentation
It is logically not possible to quantify the number of indirect deaths
15:00
to
16:30
Central square 3 (C3)
Alfred Uhl
Oral presentation
Mortality and Morbidity in Patients in Opioid Maintenance Treatment
15:00
to
16:30
Central square 3 (C3)
Roman Gabrhelík
Oral presentation
Anabolic androgenic steroid use population size estimation: a first stage study utilising a Delphi exercise
15:00
to
16:30
Knowledge market 4 (K4)
Vivian Hope
Oral presentation
Prevalence and socio-demographics correlates of cannabis vaping: Results from the 2018 & 2019 International Cannabis Policy Study
15:00
to
16:30
Knowledge market 4 (K4)
Gary Chan
Oral presentation
Systematic review and meta-analysis of the prevalence of prescription opioid dependence in patients with chronic non cancer pain (CNCP) treated with opioid painkillers
15:00
to
16:30
Knowledge market 4 (K4)
Kyla Thomas
Oral presentation
Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: the ETHOS Engage Study
15:00
to
16:30
Knowledge market 4 (K4)
Jason Grebely
Oral presentation
How does risk prevention (not) work? Learning from the realist, pragmatic, cluster-randomised trial of the RISKIT-CJS programme (with a null result)
15:00
to
16:30
Knowledge market 4 (K4)
Nadine Hendrie
Oral presentation
Association of opioid agonist treatment with mortality or rehospitalization following injection drug use-associated bacterial and fungal infections: linkage cohort study
15:00
to
16:30
Knowledge market 3 (K3)
Thomas Brothers
16:50
Oral presentation
The modelled cost-effectiveness of two psychological treatments for the reduction of alcohol consumption in alcohol-dependent individuals
16:50
to
18:20
Central square 1 (C1)
Sergio Flores
Oral presentation
Can alcohol abstinence orders reduce mortality? Insights from an individual-level analysis of 24/7 Sobriety
16:50
to
18:20
Central square 1 (C1)
Beau Kilmer
Oral presentation
Community involvement facilitating the discussion of alcohol use in primary care: A nominal group study
16:50
to
18:20
Central square 1 (C1)
Bram Pussig
Oral presentation
Modeling the Impact of a long-term horizon and multiple treatment episodes on the effectiveness and cost-effectiveness of alcohol treatment in the United States
16:50
to
18:20
Central square 1 (C1)
Carolina Barbosa
Oral presentation
Per capita alcohol consumption and alcohol-related harm: an analysis of long-term evidence from Nordic and Mediterranean countries
16:50
to
18:20
Central square 1 (C1)
Gregor Zwirn
Oral presentation
An international rapid review of the needs and an indirect estimate of the national prevalence of women who use substances and endure domestic violence.
16:50
to
18:20
Central square 3 (C3)
Catherine Comiskey
Oral presentation
1. Experimental studies on cannabis and driving impairment
16:50
to
18:20
Insights zone 3 (I3)
Tom Arkell
Oral presentation
What are the attitudes of pregnant women and mothers concerning maternal alcohol use, and what factors are associated with increased maternal drinking?
16:50
to
18:20
Central square 3 (C3)
Abi Rose
Oral presentation
2. Epidemiological studies on cannabis and crash risk
16:50
to
18:20
Insights zone 3 (I3)
Eef Theunissen
Oral presentation
Identifying the needs of mothers in substance use treatment services using electronic health records
16:50
to
18:20
Central square 3 (C3)
Martha Canfield
Oral presentation
3. Toxicology: detection of THC impairment
16:50
to
18:20
Insights zone 3 (I3)
Jan Ramaekers
Oral presentation
Metzineres. Environments of Shelter for Womxn who use drugs surviving violence
16:50
to
18:20
Central square 3 (C3)
Aura Roig Forteza
Oral presentation
4. Policy and legislation
16:50
to
18:20
Insights zone 3 (I3)
Brendan Hughes
Oral presentation
Prevalence of Tobacco Smoking in Austria. Differences between Women and Men
16:50
to
18:20
Central square 3 (C3)
Irene Schmutterer
Oral presentation
5. Medical use and novel cannabinoids
16:50
to
18:20
Insights zone 3 (I3)
Robyn Robertson
Thursday, 24 November
09:00
Oral presentation
1. Implementing patient-reported experiences (PROMs and PREMs) to improve the engagement of patients in treatment services
09:00
to
10:30
Knowledge market 4 (K4)
Joan-Ignasi Mestre-Pintó
Oral presentation
2. New challenges in drug monitoring: wastewater analysis as an alternative indicators for rapid epidemiological assessment of drug use trend
09:00
to
10:30
Knowledge market 4 (K4)
José Benito Quintana
Oral presentation
3. Promotion of health regarding the problematic drug use through interventions in educational and primary addiction treatment settings
09:00
to
10:30
Knowledge market 4 (K4)
Victor Villanueva
Oral presentation
4. Translational research as a necessary actor for fighting addiction: RIAPAd as a coordinated national cooperative framework
09:00
to
10:30
Knowledge market 4 (K4)
Fernando Rodriguez De Fonseca
Discussion
What is next on Addiction Research? A responsible innovative approach to societal changes in Addiction
09:00
to
10:30
Knowledge market 4 (K4)
Marta Torrens,
Fernando Rodriguez De Fonseca
10:50
Oral presentation
1. Global Prevalence of Heated Tobacco Product Use: A Systematic Review and Meta-analysis
10:50
to
12:20
Insights zone 4 (I4)
Tianze Sun
Oral presentation
2. HTP prevalence in England and use for smoking cessation
10:50
to
12:20
Insights zone 4 (I4)
Harry Tattan-Birch
Oral presentation
3. Perceived health risks of heated tobacco products, tobacco cigarettes, and e-cigarettes: Findings from a populationbased cross-sectional household survey in Germany (DEBRA study)
10:50
to
12:20
Insights zone 4 (I4)
Stephanie Klosterhalfen
Oral presentation
4. Harm perceptions of heated tobacco products and vaping among students at Lithuanian universities
10:50
to
12:20
Insights zone 4 (I4)
Erikas Simonavičius
Oral presentation
5. It’s not what you’d term normal smoking’: A qualitative exploration of HTP user identity
10:50
to
12:20
Insights zone 4 (I4)
Katherine A. East
Oral presentation
Experienced gratification and compensation in addictive behaviors: Investigating its relevance in different types of Internet-use disorders
10:50
to
12:20
Insights zone 3 (I3)
Stephanie Antons
Oral presentation
Understanding first controlled gaming in teenagers. A qualitative study among young French daily or week-end gamers
10:50
to
12:20
Insights zone 3 (I3)
Carine Mutatayi
Oral presentation
Assessment of Criteria for Specific Internet-use Disorders (ACSID-11):Further development and validation of a new screening instrument capturing ICD-11 criteria for gaming disorder and other potential Internet-use disorders
10:50
to
12:20
Insights zone 3 (I3)
Andreas Oelker
Oral presentation
Problematic gaming risk among European adolescents: A cross-national evaluation of individual and socio-economic factors
10:50
to
12:20
Insights zone 3 (I3)
Sabrina Molinaro
Oral presentation
Effects of COVID-19 lockdowns on addiction to social networking sites and associations with changes in loneliness, sexual functioning, and eating styles
10:50
to
12:20
Insights zone 3 (I3)
Rui Costa
Oral presentation
2. Patterns of problematic cannabis use among Canadian and US respondents between 2018 and 2020: Findings from the International Cannabis Policy Study
10:50
to
12:20
Knowledge market 1 (K1)
Cesar Leos-Toro
Oral presentation
3. Perceptions of illegal and legal cannabis in Canada in the three years after cannabis legalization: Findings from the International Cannabis Policy Study
10:50
to
12:20
Knowledge market 1 (K1)
TBD TBD
Oral presentation
1. The International Cannabis Policy Study – Framework for evaluating cannabis legalization
10:50
to
12:20
Knowledge market 1 (K1)
David Hammond
13:20
Oral presentation
2. Estimating the prevalence of opioid dependence in New South Wales from multiple data sources: case study application of a Bayesian modelling approach
13:20
to
14:50
Central square 2 (C2)
Hayley E. Jones
Oral presentation
3. Estimates of people who injected drugs within the past 12 months in France
13:20
to
14:50
Central square 2 (C2)
Eric Janssen
Oral presentation
4. How many people injected illicit drugs in the European Union in 2019?
13:20
to
14:50
Central square 2 (C2)
Filippo Pericoli
Oral presentation
1. Estimates of people who injected drugs within the last 12 months in Belgium
13:20
to
14:50
Central square 2 (C2)
Luk Van Baelen
Oral presentation
5. Updated global estimates of prevalence of People Who Inject Drugs and coverage of harm reduction – what has changed between 2017 and 2021
13:20
to
14:50
Central square 2 (C2)
Samantha Colledge-Frisby
15:00
Short communication
Benefits and Challenges of Integrating Yoga in Government-Funded Substance Addiction Treatment Programs in India: Results from a Mixed Methods Research Study with Exploratory Sequential Design.
15:00
to
16:30
Networking zone 3 (N3)
Sebastian Perumbilly,
Jake Zoubek,
Aubrey Grodin
Oral presentation
1. Developing and Extending Evidence and Practice from the Standard European Alcohol Survey (DEEP SEAS): Key findings, strengths, and limitations
15:00
to
16:30
Central square 1 (C1)
Carolin Kilian
Short communication
The global burden of alcohol use disorders: methodological considerations
15:00
to
16:30
Networking zone 3 (N3)
Laura Jones
Oral presentation
2. Lessons for the future of alcohol surveys
15:00
to
16:30
Central square 1 (C1)
Jürgen Rehm
Discussion
The future of surveys in the field of alcohol research
15:00
to
16:30
Central square 1 (C1)
Charlotte Probst,
Bernd Schulte
Short communication
Structured Leisure Activities (SLA) and Adolescent Alcohol Use
15:00
to
16:30
Networking zone 3 (N3)
Matea Belošević
Short communication
Social networks amongst people with alcohol dependence who frequently attend hospital: an exploratory qualitative study
15:00
to
16:30
Networking zone 3 (N3)
Stephanie Fincham-Campbell
Short communication
Alcohol and other drug use and treatment for Aboriginal Australians involved in the criminal justice system
15:00
to
16:30
Networking zone 3 (N3)
Michael Doyle
Short communication
Effectiveness of regulatory policies on online/digital/internet – mediated alcohol marketing: a systematic review
15:00
to
16:30
Networking zone 3 (N3)
Sandra Rados Krnel
Short communication
Outcomes of a health economic evaluation of digital alcohol and tobacco interventions for cancer survivors alongside randomized controlled trials
15:00
to
16:30
Networking zone 3 (N3)
Matthijs Blankers
Short communication
Impact of digital alcohol marketing on alcohol-related attitudes and alcohol consumption
15:00
to
16:30
Networking zone 3 (N3)
Wim Van Dalen
Oral presentation
1. New Psychoactive Substance Presentations to the Euro-DEN Plus Network
15:00
to
16:30
Central square 2 (C2)
Benjamin Crulli
Oral presentation
2. The clinical impact of ethanol co-use in patients with acute drug toxicity involving the use of central nervous system depressant recreational drugs
15:00
to
16:30
Central square 2 (C2)
Eva-Carina Heier
Oral presentation
3. Variation in the drugs involved in acute drug toxicity presentations based on age and sex within the Euro-DEN Plus dataset
15:00
to
16:30
Central square 2 (C2)
Òscar Miró
Oral presentation
4. Deaths among acute drug toxicity presentations to the Euro-DEN Plus Network, 2014-2020
15:00
to
16:30
Central square 2 (C2)
Isabelle Giraudon
Oral presentation
3. Are there good alternatives or add ons to surveys?
15:00
to
16:30
Central square 1 (C1)
Pia Mäkelä
Oral presentation
0. Insights into acute recreational drug and NPS toxicity: an update from the Euro DEN Plus Project: Introduction
15:00
to
16:30
Central square 2 (C2)
Paul Dargan
16:50
Oral presentation
The acceptability and feasibility of implementing and evaluating the Parents under Pressure (PuP) parenting programme with opioid-dependent fathers and their families: results from the PuP4Dads study.
16:50
to
18:20
Central square 3 (C3)
Anne Whittaker
Oral presentation
Suicide and self-harm during COVID-19 and beyond.
16:50
to
18:20
Main stage
Navneet Kapur
Oral presentation
Adolescent substance use, self-harm and suicide: Findings from the Northern Finland Birth Cohort 1986.
16:50
to
18:20
Main stage
Solja Niemelä
Oral presentation
Restricting access to means: Public health approaches to reduce drug- and alcohol-related self-harm.
16:50
to
18:20
Main stage
Eve Griffin
Oral presentation
Identification of cannabis user profiles and their engagement with polydrug use among respondents of the European Web Survey on Drugs: findings from Luxembourg
16:50
to
18:20
Knowledge market 3 (K3)
Tom Kugener
Oral presentation
E-cigarette use and conventional cigarette smoking among high school students in 35 European countries: findings from the 2019 ESPAD survey
16:50
to
18:20
Knowledge market 3 (K3)
Sonia Cerrai
Oral presentation
Laughing gas (N2O) in The Netherlands: where a quick rise in use required action
16:50
to
18:20
Knowledge market 3 (K3)
Desiree Spronk
Oral presentation
Identifying subgroups of Dutch cannabis users based on help-seeking preferences: a latent class analysis
16:50
to
18:20
Knowledge market 3 (K3)
Marleen Olthof
Oral presentation
A National Recovery Study in Higher Education Institutions in Ireland
16:50
to
18:20
Knowledge market 3 (K3)
Ivers Jo-Hanna
e-poster
Take-Home Naloxone and risk management among people who survived an opioid overdose; a qualitative analysis informed by drug, set and setting
16:50
to
18:20
Networking zone 1 (N1)
Elin Holmén
Oral presentation
EXtended-release Pharmacotherapy for Opioid Use Disorder (EXPO)
16:50
to
18:20
Central square 3 (C3)
John Marsden
e-poster
Mortality and causes of death among persons with alcohol use disorder only versus persons with opioid dependence: results from a 19-year prospective cohort study.
16:50
to
18:20
Networking zone 1 (N1)
Ivar Skeie
Oral presentation
Characteristics of concerned persons (CPs) accessing treatment services in their own right: A secondary analysis of Irish health data for 2010-2020.
16:50
to
18:20
Central square 3 (C3)
Cathy Kelleher
e-poster
Identifying and tracking cases of suspected unintentional drug overdose deaths in near real-time using the Suspected Potential Overdose Tracker (SPOT)
16:50
to
18:20
Networking zone 1 (N1)
Karli Hochstatter
e-poster
Wearable technologies that may prevent, detect or respond to opioid overdose: a scoping review.
16:50
to
18:20
Networking zone 1 (N1)
Basak Tas
e-poster
Harm reduction behaviors are associated with carrying naloxone among patients on methadone treatment.
16:50
to
18:20
Networking zone 1 (N1)
Zofia Kozak
e-poster
Knowledge and attitude of community stakeholders towards harm reduction activities including Methadone treatment, needle and syringe exchange programs for drug users and injectors in Gaza Strip-Palestine (2019)
16:50
to
18:20
Networking zone 1 (N1)
Mohammed fathi Alafifi
e-poster
High smoking and low cessation rates among patients in treatment for opioid and other substance use disorders
16:50
to
18:20
Networking zone 1 (N1)
Endre D. Bjørnestad
e-poster
Hepatitis C seroprevalence and associated factors among people who inject drugs (PWID) in Estonia
16:50
to
18:20
Networking zone 1 (N1)
Sigrid Vorobjov
e-poster
An ecological analysis of the spatial relationship between a network of supervised consumption services and overdose mortality incidence in Toronto, Canada.
16:50
to
18:20
Networking zone 1 (N1)
Indhu Rammohan
Oral presentation
Ayahuasca-assisted addiction treatment in Peru: qualitative results from a multi-year, mixed-methods study
16:50
to
18:20
Central square 3 (C3)
Olivia Marcus
Oral presentation
2. Characteristics associated with drug use during the current detention – results from prison surveys in 4 EU countriessurveys in 4 EU countries
16:50
to
18:20
Central square 1 (C1)
Els Plettinckx
Oral presentation
5. Social determinants, health service contacts and incarceration among all those dying from an accidental overdose 2010-2018 in Norway
16:50
to
18:20
Central square 1 (C1)
Ellen J. Amundsen
Oral presentation
3. Reimprisonment rates among men who inject drugs in Victoria, Australia
16:50
to
18:20
Central square 1 (C1)
Ashleigh C. Stewart
Oral presentation
4. Adverse childhood experiences, substance use, and involvement with correctional services
16:50
to
18:20
Central square 1 (C1)
Richard Pates
Oral presentation
6. Wasted': the complex trajectories from incarceration to recovery. A personal experience
16:50
to
18:20
Central square 1 (C1)
Mark Johnson Ferguson
Discussion
Common pathways to problematic drug use and incarceration and lessons learnt for policy and practice
16:50
to
18:20
Central square 1 (C1)
Liesbeth Vandam
Oral presentation
1. Use pathways in prison. A French literature review
16:50
to
18:20
Central square 1 (C1)
Caroline Protais
Friday, 25 November
09:00
Keynote presentation
What did we learn about recent trends in underage drinking: Secular trends, shifts, and relations to other substance use
09:00
to
10:30
Main stage
Jasmina Burdzovic
Keynote presentation
Can brief interventions ever really take on the alcohol industry and win?
09:00
to
10:30
Main stage
Jim McCambridge
Keynote presentation
A social inequities viewpoint to reducing alcohol-related harm
09:00
to
10:30
Main stage
Pia Mäkelä
10:50
Oral presentation
5. The impacts of COVID-19 pandemic on drug purchasing behaviours of people who use methamphetamine in Victoria, Melbourne.
10:50
to
12:20
Insights zone 4 (I4)
Kasun Rathnayake
Oral presentation
2. A rapid assessment of take-home naloxone provision during COVID-19 in Europe
10:50
to
12:20
Insights zone 4 (I4)
Rebecca Mc Donald
Oral presentation
3. Will they accept the vaccine? A 2021 COVID-19 survey among 477 people who use drugs in Norway
10:50
to
12:20
Insights zone 4 (I4)
Gabrielle K. Welle-Strand
Oral presentation
1. Revised service delivery of opioid agonist treatment in Norway in 2021, the second year of the pandemic: a national cross-sectional study of treatment provider experiences
10:50
to
12:20
Insights zone 4 (I4)
Anne Berit Bech
Oral presentation
4. Have predictors of drug addiction relapse changed during the COVID-19 pandemic? A prospective study of recovery pathways in the Netherlands, Belgium and UK
10:50
to
12:20
Insights zone 4 (I4)
Thomas Martinelli
Oral presentation
Increased risk of non-fatal overdose associated with NPS-type [‘street’] benzodiazepine use in Scotland, UK
10:50
to
12:20
Knowledge market 3 (K3)
Andrew McAuley
Oral presentation
Variations in the protective association between opioid agonist therapy and opioid overdose death by age and chronic disease status: findings from the OATS retrospective linked data study, NSW, Australia, 2001-2018.
10:50
to
12:20
Knowledge market 3 (K3)
Sarah Larney
Oral presentation
Temporal trend in the survival of injecting and non-injecting heroin-dependent patients admitted to treatment in Barcelona, Spain: a 30-year cohort study.
10:50
to
12:20
Knowledge market 3 (K3)
Anna Hernández-Rubio
Oral presentation
The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018.
10:50
to
12:20
Knowledge market 3 (K3)
Nicola Jones
Oral presentation
Factors associated with mortality in The Norwegian Offender Mental Health and Addiction (NorMA)- cohort
10:50
to
12:20
Central square 1 (C1)
Torill Tverborgvik
Oral presentation
All cause and cause specific mortality among individuals imprisoned for driving under the influence of alcohol and drugs in Norway (2000-2016)
10:50
to
12:20
Central square 1 (C1)
Ragnhild Jamt
Oral presentation
The Impact of Co-Occurring Mental Health Problems on Referral to and Initiation of Treatment Among Youth Under Probation Supervision
10:50
to
12:20
Central square 1 (C1)
Steven Belenko
Oral presentation
(Ex-)inmates' substance use: a needs assessment based on semi-structured interviews
10:50
to
12:20
Central square 1 (C1)
Nicky Dirkx
Oral presentation
Prevalence of heroin drug use before and during imprisonment in Europe: results from a comprehensive literature review and analysis of prevalence data in six European countries
10:50
to
12:20
Central square 1 (C1)
Sara Mazzilli
Oral presentation
European Web Survey on Drugs
10:50
to
12:20
Central square 4 (C4)
João Matias,
José Pedro Teixeira
Oral presentation
European Web Survey on Drugs - Luxembourg
10:50
to
12:20
Central square 4 (C4)
Rita Cardoso Seixas
Oral presentation
European Web Survey on Drugs - Ireland
10:50
to
12:20
Central square 4 (C4)
Nicki Killeen
Oral presentation
The experience of running web surveys in Belgium
10:50
to
12:20
Central square 4 (C4)
Elena Damian
Oral presentation
Web surveys on drugs - how can these be important for those who use drugs
10:50
to
12:20
Central square 4 (C4)
Lígia Parodi
13:20
Oral presentation
Monitoring online illicit drug market during the COVID-19 in Georgia
13:20
to
14:50
Insights zone 4 (I4)
Irma Kirtadze
Oral presentation
Who buys drugs using online sources in Ireland? Findings from the European Web Survey on Drugs
13:20
to
14:50
Insights zone 4 (I4)
Deirdre Mongan
Oral presentation
What can we learn from low-THC cannabis growers in Europe? A comparative transnational study of 1635 small-scale cannabis growers in Italy and Switzerland
13:20
to
14:50
Insights zone 4 (I4)
Davide Fortin
Oral presentation
Brokered Illegal Drug Sales as a Measure of Local Demand
13:20
to
14:50
Insights zone 4 (I4)
Georgiy Bobashev
Short communication
Social alcohol cue reactivity in the brain: role of craving and social processes in adolescent and adult alcohol users
13:20
to
14:50
Networking zone 4 (N4)
Lauren Kuhns
Short communication
Alcohol Poisoning Outbreak in Iranian Adult Population During the COVID-19 Pandemic: A Prospective Cross-sectional Linkage Study from 13 Toxicology Referral Centers in Iran
13:20
to
14:50
Networking zone 4 (N4)
Hossein Hassanian-Moghaddam
Short communication
Novel interventions to help citizens with hazardous substance use and prevent driving under the influence of alcohol or drugs (DUI)
13:20
to
14:50
Networking zone 4 (N4)
Kristine Rømer Thomsen
Short communication
Young, drunk, and fast: the paradoxical effects of hazardous drinking on cognitive performance in younger adults
13:20
to
14:50
Networking zone 4 (N4)
Anna Powell
Short communication
A Literature Review, using a Systematic Approach, on Effective Interventions and Approaches in the Delivery of Integrated Alcohol Services in Community Settings
13:20
to
14:50
Networking zone 4 (N4)
Elizabeth McCarthy
Short communication
Influence of alcohol use and other addictive disorders in the costs of emergency department frequent use
13:20
to
14:50
Networking zone 4 (N4)
Clara Oliveras Salvà
Oral presentation
Comparing characteristics of suicide to non-suicide drug poisoning, by sex, in Ireland.
13:20
to
14:50
Knowledge market 2 (K2)
Ena Lynn
Oral presentation
Characteristics associated with suicide among people who use drugs in Ireland 2015 to 2017: a repeated cross-sectional study
13:20
to
14:50
Knowledge market 2 (K2)
Suzi Lyons
Oral presentation
Implementation of a community-based psychiatric intervention among people who inject drugs in the City of Haiphong, Vietnam: the DRIVE-Mind project
13:20
to
14:50
Knowledge market 2 (K2)
Laurent Michel
Oral presentation
Hazardous, harmful and dependent alcohol use in Crisis Resolution Team patients: relationship with death or service recontact after a suicidal crisis.
13:20
to
14:50
Knowledge market 2 (K2)
John Robins
Short communication
Initial efficacy of a new goal-oriented intervention for impulsive and sensation-seeking adolescents involving a digital game and MI-based interview
13:20
to
14:50
Networking zone 4 (N4)
Nuri Wieland
Oral presentation
The impact of detoxification on suicidal behaviour among heroin users: longitudinal data from South Africa
13:20
to
14:50
Knowledge market 2 (K2)
Nirvana Morgan
Oral presentation
TitleDeterminants of psychological distress during the COVID-19 pandemic among people who use drugs in Montreal, Canada
13:20
to
14:50
Knowledge market 2 (K2)
Iuliia Makarenko
Oral presentation
Alcohol, tobacco and cannabis use and mental health as well as other associated factors during the COVID-19 pandemic among German university students
13:20
to
14:50
Knowledge market 2 (K2)
Stefanie Helmer
Oral presentation
Cannabis regulation and fiscal policy: Opportunities for human rights in Colombia
13:20
to
14:50
Knowledge market 1 (K1)
Luis Felipe Cruz-olivera
Oral presentation
Prioritising measures to assess performance of drug treatment services: perspectives of funders, treatment providers and service users
13:20
to
14:50
Knowledge market 1 (K1)
Robert Stirling
Oral presentation
Tracking the illicit Cannabis Market during the closed Cannabis Supply Chain Experiment in Netherlands using an online Crowdsourcing Approach
13:20
to
14:50
Knowledge market 1 (K1)
Stijn Hoorens
Oral presentation
Triangulating wastewater and a prospective survey of drug consumption – new insights for policy makers
13:20
to
14:50
Knowledge market 1 (K1)
Caitlin Hughes
Oral presentation
The effects of cannabis liberalization laws on health, safety, and socioeconomic outcomes: An evidence and gap map
13:20
to
14:50
Knowledge market 1 (K1)
Eric Sevigny
e-poster
A systematic review of self-report and behavioural measures of the Addiction Neuroclinical Assessment constructs of incentive salience and negative emotionality, in adults who use psychoactive drugs.
13:20
to
14:50
Networking zone 2 (N2)
Maria Bravo Aguilera
e-poster
Abuse of prescription psychoactive medicines
13:20
to
14:50
Networking zone 2 (N2)
Darja Lavtar
e-poster
Changes in substance use during the COVID-19 pandemic: Longitudinal analysis of risk behavior and mental health of MSM using HIV pre-exposure prophylaxis
13:20
to
14:50
Networking zone 2 (N2)
Babette Lea Winter
e-poster
Non-prescribed buprenorphine and reduction in illicit opioids use among individuals with opioid use disorder: a longitudinal study
13:20
to
14:50
Networking zone 2 (N2)
Raminta Daniulaityte
e-poster
Sexualized substance use, consumption motives and risk factors for relapse of addiction patients. Results of a cross-sectional study in addiction treatment facilities in Germany.
13:20
to
14:50
Networking zone 2 (N2)
Daniel Deimel
e-poster
How hair keeps track: Associations between hair concentrations of psychoactive substances and steroid hormones in a large cohort sample of young adults in Switzerland
13:20
to
14:50
Networking zone 2 (N2)
Lydia Johnson-Ferguson
e-poster
Changes in sexualised and non-sexualised drug use among LGBT+ people during the COVID-19 pandemic: A systematic review
13:20
to
14:50
Networking zone 2 (N2)
Dean Connolly
e-poster
Four-year long wastewater-based monitoring of illicit drug consumption pilot project in Switzerland
13:20
to
14:50
Networking zone 2 (N2)
Livia Andrani
e-poster
How are profiles of substance use linked to social function in the following seven years?
13:20
to
14:50
Networking zone 2 (N2)
Sidsel Karsberg
Oral presentation
1. A novel way of enhancing adherence to acamprosate for alcohol dependence: The Alcohol Dependence and Adherence to Medicine (ADAM) trial
13:20
to
14:50
Networking zone 3 (N3)
Thomas Phillips
Oral presentation
2. Effectiveness and cost-effectiveness of face-to-face and electronic brief interventions versus screening alone to reduce alcohol consumption among high-risk adolescents presenting to Emergency Departments: three-arm pragmatic randomised trial
13:20
to
14:50
Networking zone 3 (N3)
Paolo Deluca
Oral presentation
3. Alcohol Assertive Outreach Treatment randomised controlled trial: a mixed methods economic evaluation
13:20
to
14:50
Networking zone 3 (N3)
Amy Wolstenholme
Discussion
Lessons for future clinical research trials and clinical practice
13:20
to
14:50
Networking zone 3 (N3)
Karl Mann
e-poster
Suicide and self-harm among people prescribed opioid agonist treatment in New South Wales: a retrospective data linkage study
13:20
to
14:50
Networking zone 2 (N2)
Samantha Colledge-Frisby
15:00
Keynote presentation
Early warnings and outbreaks: A sociological perspective
15:00
to
15:30
Main stage
Tim Rhodes
Introduction
Richard Hartnoll – a seminal contributor to the development of the EMCDDA and drug epidemiology
15:00
to
15:30
Main stage
Paul Griffiths